CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices
NEWNAN, Ga., Dec. 1 /PRNewswire/ — CeloNova BioSciences, Inc., a provider of specialty surface treatments for medical devices and of specialty implants, today announced that President and Chief Executive Officer, Thomas A. Gordy, will give an opening address for the Technology Parade at the Innovations in Cardiovascular Interventions Conference in Tel Aviv, Israel. “We must leave the era of petty self-interest behind and focus the rich intellectual resources of the health care industry toward collaboration, innovation, and rapid market entry. We need more heart, more passion, and more integrity. With laser-like focus, we can truly heal the world,” said Gordy. “The international faculty at ICI is renowned for spotlighting transformative technology.”
About CeloNova BioSciences: Headquartered in Newnan, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are enhanced by one of the Company’s proprietary materials, PolyzeneÃ‚®-F, a lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant surface treatment for implanted medical devices. The Company’s current products include Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin PolyzeneÃ‚®-F. Both products are CE Marked. Embozene(TM) Microspheres have been approved by the FDA for the treatment of hypervascularized tumors and arteriovenous malformations. For more information, please visit www.celonova.com
About Innovations in Cardiovascular Interventions: The ICI meeting for interventional cardiologists, innovators, and industry will be held December 6-8, in Tel-Aviv, Israel. It is a continuation of the series of interventional cardiology conferences held in Israel since 1995. The upcoming meeting will focus on innovative technology, therapies, and research at various levels of development, with thematic live case presentations to present the impact of these technologies on current and future therapy.
Contact: Theresa Wilson (770) 502-0304; (678) 895-6486
SOURCE CeloNova BioSciences, Inc.